This content is machine translated NSCLC Bispecific antibodies for rare EGFR mutations Rare EGFR mutations such as exon 20 insertion changes have long been considered a therapeutic dead end in non-small cell lung cancer (NSCLC). Current data show that innovative mechanisms of...…
